COVID-19 antibodies enable tissue-based detection of viral infection

HistoSure’s novel monoclonal COVID-19 antibodies developed to enable tissue-based detection of viral infection in human clinical samples have shown excellent performance in ELISA-based detection of viral nucleocapsid protein.

HistoSure, a product line of Synaptic Systems GmbH, a renowned developer and manufacturer of antibodies, is dedicated to providing highly validated and tested antibodies for pre-clinical and clinical research. As the Covid-19 pandemic progresses, reliable antibodies to investigate the effects of SARS-CoV-2 in the human body become increasingly important. HistoSure offers two highly specific mouse monoclonal antibodies directed against the SARS-CoV-2 nucleocapsid protein. Both have been developed and tested to ensure superior performance on FFPE tissue (IHC-P), IHC and in ELISA applications.

  • Clone 4A8 mouse anti-SARS-CoV-2 nucleocapsid protein (Isotype IgG2b) (cat. no. HS-452 011)
  • Clone 53E2 mouse anti-SARS-CoV-2 and SARS-CoV-1 nucleocapsid protein (Isotype IgG2a) (cat. no. HS-452 111)

SARS-CoV-2 nucleocapsid antibodies detect virus-infected cells in human clinical samples

The SARS-CoV-2 nucleocapsid antibodies from HistoSure are especially useful to detect virus-infected cells in formalin-fixed paraffin-embedded human clinical samples. The Medical Center Hamburg-Eppendorf (UKE) located in Hamburg, Germany has successfully implemented the SARS-CoV-2 nucleocapsid antibodies from HistoSure for detection of viral components in the lungs of COVID-19 patients using automated slide staining systems.

Nucleocapsid antibody (Clone 4A8, cat. no. HS-452 011, 1:1000; Dres. Krasemann, Heinrich/Pfefferle from UKE-Hamburg/Germany.

SARS-CoV antibodies enable virus research in mouse models of COVID-19 infection

K18-hACE2 transgenic mice are powerful models of severe COVID-19 disease. Few days after intranasal viral inoculation, infectious virus is detected in various organs and in the nervous system. In cooperation with Prof. Kröger and Prof. Cicin-Sain of the Helmholtz Center for Infection research in Braunschweig, Germany, SARS-CoV-2 nucleocapsid antibodies from HistoSure have been shown to enable cellular detection of viral particles in infected mouse organs.

Indirect immunostaining of PFA fixed mouse brain sections monoclonal anti-SARS-CoV-2 nucleocapsid antibody clone 4A8 (cat. no. HS-452 011, dilution 1:1000; red)

Synaptic System supports Sars-CoV-2 and Sars-CoV-1 research by providing virus subtype-specific antibodies

The SARS-CoV-2 nucleocapsid antibodies from HistoSure are especially useful to discriminate SARS-CoV-1 and Sars-CoV-2 viral particles as clone 4A8 recognises exclusively the SARS-CoV-2 nucleocapsid whereas clone 53E2 recognizes SARS-CoV-1 and SARS-CoV-2 nucleocapsid proteins. Both antibodies have been shown to not bind nucleocapsid proteins of other coronavirus strains.

COVID-19 antibodies show excellent performance in ELISA-based detection of viral nucleocapsid protein

The SARS-CoV-2 nucleocapsid antibodies from HistoSure show superior performance in Sandwich ELISA settings and enable quantitative viral nucleocapsid detection in liquid samples.

Clone #4A8 (cat.no. HS-452 011) was coated as capture antibody and Biotinylated clone #53E2 (cat.no. HS-452 111BT, 1:2000) was used as a detection antibody.



For more information on Synaptic Systems HistoSure COVID-19 antibodies clone 4A8 (cat. no. HS-452 011) and clone 53E2 (cat. no. HS-452 111 and cat. no HS-452 111BT) complete the enquiry form or email: sales@sysy.com


    • histosure 6 768x480

    HistoSure

);